Sangamo Therapeutics (SGMOQ) Capital Expenditures Growth (5y) (2015 - 2025)
Analysis
Sangamo Therapeutics (SGMOQ) Capital Expenditures Growth (5y) (2015 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.28 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.54 Bn | 251.87 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -67.75% |
| Sep 30, 2025 | -14.91% |
| Jun 30, 2025 | -15.39% |
| Mar 31, 2025 | -42.66% |
| Sep 30, 2024 | -14.91% |
| Jun 30, 2024 | -14.90% |
| Mar 31, 2024 | -40.12% |
| Dec 31, 2023 | -37.51% |
| Sep 30, 2023 | -21.59% |
| Jun 30, 2023 | 11.94% |
| Mar 31, 2023 | 31.28% |
| Dec 31, 2022 | 53.47% |
| Sep 30, 2022 | 44.60% |
| Jun 30, 2022 | 26.11% |
| Mar 31, 2022 | 43.41% |
| Dec 31, 2021 | 31.58% |
| Sep 30, 2021 | 23.05% |
| Jun 30, 2021 | 134.24% |
| Mar 31, 2021 | 99.27% |
| Dec 31, 2020 | 116.67% |